摘要
目的:评价重组人p53腺病毒注射液(rAd-p53)联合化疗治疗化疗耐药的晚期恶性肿瘤患者的近期临床疗效及安全性.方法:化疗耐药的晚期恶性肿瘤患者15例,均为rAd-p53腺病毒注射液联合化疗.治疗前后检测p53癌基因蛋白阳性率、肿瘤标记物等,观察不良反应.卡氏评分评估体力状态的变化,综合评估患者的临床受益.结果:治疗后患者的临床获益率为73.3%(11/15),有效率33.3%(5/15).不良反应多为自限性.p53癌基因蛋白治疗前阳性率为52.4%,治疗后为50.7%,治疗前后无明显变化.卡氏评分平均提高≥10分.结论:rAd-p53腺病毒联合化疗可能对化疗耐药的晚期恶性肿瘤患者有效;患者可耐受该种治疗.
AIM： To evaluate the recent therapeutic effect and safety of recombinant human p53 adenovirus injection （ rAd-p53 ） in the treatment of chemotherapy tolerant advanced tumors. METHODS： Fifteen patients who had chemotherapy tolerant advanced tumors were injected with rAd-p53. The p53 oncogene positive rate, tumor markers and side effects were tested and observed. The Karnofsky score （KPS） was used to assess the performance status and the clinical improvements of the patients. RESULTS： The clinical beneficial rate of patients was 73.3% （11/15）, effective rate was 33.3% （5/15）. The side effects were self-restricted. The preoperative positive rate of 1353 oncogene protein was 52.4%, and changed to 50.7% after treatment. The positive rate of p53 oncogene protein did not obviously change after such a treatment. The average increase of KPS was ≥10. CONCLUSION： The rAd-p53 combined chemotherapy is an effective and tolerant way to treat patients with chemotherapy tolerant advanced tumors.
出处
《第四军医大学学报》
CAS
北大核心
2008年第11期1034-1036,共3页
Journal of the Fourth Military Medical University
基金
黑龙江省卫生厅科研课题(2006-221)
